NALIRIFOX chemotherapy for locally advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) as a first treatment for people with locally advanced pancreatic cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with locally advanced pancreatic cancer that has not spread to other organs.
- You have not had any chemotherapy, targeted therapy, or immunotherapy for this cancer before.
- Your general health must be good (able to do daily activities, with normal organ function).
- You must be willing to use effective birth control during and after the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies Nalirifox (chemotherapy) given together with radiation therapy for pancreatic ductal adenocarcinoma that has not spread to distant organs. It may help shrink the cancer and improve local control, especially when surgery is not an option right now.
This study tests a monthly rotation of two chemotherapy combinations (NALIRIFOX and GnP) as the first treatment for metastatic pancreatic cancer. The goal is to see if alternating the drugs helps control the cancer while reducing side effects.
This trial tests a combination chemotherapy called NALIRIFOX as a second treatment for people with advanced high-grade neuroendocrine cancers. The goal is to see if it can help when the first treatment didn't work.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This trial compares two different chemotherapy combinations, each paired with immunotherapy and radiation, as the first treatment for locally advanced pancreatic cancer. It aims to see which combination works better.
This trial tests a new drug combination (NALIRIFOX plus immunotherapy) followed by radiation, compared to NALIRIFOX alone, as a way to shrink pancreatic tumors that haven't spread and make them removable. It's for people who haven't had any previous cancer treatment.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.